Brevan Howard Capital Management 13F: Cuts ASND Stake by $5.9M
Brevan Howard Capital Management cut its holdings in Ascendis Pharma ASND by 45.7% in a filing submitted to the SEC.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brevan Howard Capital Management sold 22,060 shares from its stake in Ascendis Pharma A ($ASND), a 45.71% decrease, according to a 13F filing with the SEC dated May 15, 2026. It reported 26,200 shares worth $6.99 million at the end of the quarter.
Since the filing, $ASND is up 2.7% after 1 week, down 7.2% after 1 month and down 6.3% to date (from the $240.50 close on May 15, 2026).
Find the original: Brevan Howard Capital Management 13F filings on SEC EDGAR
ASND
Ascendis Pharma A
Key Points
- Brevan Howard Capital Management cut its stake in Ascendis Pharma A/S (NasdaqGS: ASND) by 45.7% during the quarter ended May 15, 2026, selling 22,060 shares to leave its holding at 26,200 shares valued at about $6.99 million.
- The stock trades around $266.72, moving past its 50-day moving average of $254.17 after coming off a recent earnings report released on April 30, 2026.
- Wall Street firms remain mostly positive on the drug maker, with covering institutions keeping a strong buy recommendation backed by targets spanning up to $357.32.
Get $ASND trade alerts by text
We text you when insiders, Congress or big funds trade $ASND. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Ascendis Pharma A alert may contain errors. Disclosures
Brevan Howard Trims Holdings in Ascendis Pharma ASND
Brevan Howard Capital Management reduced its investment in Ascendis Pharma A/S (NasdaqGS: ASND) during its period ended May 15, 2026, according to a Form 13F filing with the U.S. Securities and Exchange Commission. The fund cut 22,060 shares, marking a 45.7% decrease from its prior total. That left the firm with 26,200 shares of the biotechnology company, carrying a reported value of about $6.99 million.
Ascendis Pharma Stock Price Movement
Shares changed hands around $266.72 as the market digested the portfolio adjustment. The stock has spent recent months trading above its 200-day moving average of $234.59 and near its 50-day moving average of $254.17. Investors should remember that 13F disclosures are historic snapshots looking backward and might not reflect the fund's current holdings today.
Recent Earnings Performance
Ascendis Pharma reported financial results for its quarter ending on April 30, 2026, showing full-year revenue of $1.05 billion alongside an earnings per share figure of $12.83. The biopharmaceutical firm posted a net profit margin of 70.8% and a return on equity of 1.2%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
3 target raises vs 1 cuts.
-
EPS & revenue
EPS missed estimates by 471.1%. Revenue missed estimates by 9.0%.
-
Profit surprise
EBITDA missed by 9 percent. Operating income missed by 8 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
3 target raises, 1 target cut.
-
Earnings quality
Gross margin up 8.7 points. Operating margin up 113.3 points. Negative free cash flow.
Earnings Call Summary
Ascendis reported first quarter revenue of about $251 million, down slightly from the $276 million consensus expected, but beat earnings expectations at $0.32 per share versus $0.21 expected. YORVIPATH contributed $197 million in revenue but was hit by about $15 million in one-time headwinds. YUVIWEL, their new hypochondroplasia treatment approved in February, saw about 60 children prescribed in just four to five weeks after launch, showing strong unmet need. The company is now profitable with a 22 percent non-IFRS operating margin and plans to give full-year guidance after the next quarter.
Guidance Management did not provide full year revenue or earnings guidance. Instead, they said they will give updated 2026 guidance after Q2 results. They expect strong sequential growth in YORVIPATH in Q2 after one-time disruptions reversed. YUVIWEL launch is tracking much stronger than hoped.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Analysts Set New Price Targets
Wall Street research desks continue to follow the healthcare company with generally favorable views. On September 25, 2026, Cantor Fitzgerald reiterated its overweight rating with a target of $300.00. Earlier on September 15, 2026, Raymond James kept an outperform rating with a target of $287.00. Oppenheimer maintained an outperform rating on September 2, 2026, pushing its target to $312.00 from $304.00. Morgan Stanley kept an overweight rating on September 1, 2026, with a $273.00 target, while Wedbush maintained its outperform rating with a $327.00 target on the same day. Later in the month on August 31, 2026, B of A Securities held a buy rating with a $304.00 target, Jefferies maintained a buy rating with a $330.00 target, and Stifel kept a buy rating with a $326.00 target. The stock holds a consensus strong buy rating from 20 analysts with a mean price target of $311.65.
About Ascendis Pharma A/S
Ascendis Pharma A/S works as a biopharmaceutical company based in Hellerup, Denmark. The enterprise focuses on developing therapies that address unmet medical needs through its TransCon platform. Its portfolio includes SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for chronic hypoparathyroidism, alongside several rare disease and oncology candidates.
What to Watch at Ascendis Pharma A/S
Market participants will look to upcoming institutional filings and future earnings announcements to see how major funds adjust their positions in the biotech firm. Because 13F filings are delayed reports, they offer a retrospective view of portfolio changes rather than real-time trading updates.
Related Filing Alerts
Source: Brevan Howard Capital Management's 13F filing on $ASND (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Brevan Howard Capital Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts